Matinas Biopharma Hl (MTNB)

$0.56 -0.03 (-4.41%)
Market Cap 4.10M
Revenue (ttm) 0.00
Net Income (ttm) -10.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,670
Avg Vol 28,100
Day's Range N/A - N/A
Shares Out 6.41M
Stochastic %K 21%
Beta 1.61
Analysts Strong Buy
Price Target $50.00

Company Profile

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of asp...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 484 8805
Address:
1545 Route 206 South, Suite 302, Bedminster, United States
Daveo460
Daveo460 May. 12 at 2:01 AM
$MTNB the monthly chart looks good 😂
2 · Reply
Navtalk
Navtalk May. 8 at 11:51 AM
$MTNB any new in revise split?
0 · Reply
TheLawman
TheLawman May. 3 at 7:01 PM
$MTNB What has JJ been doing the last few years to earn his bloated salary?
0 · Reply
24k369
24k369 Apr. 30 at 4:50 AM
$MTNB Green Pastures
0 · Reply
emuziek
emuziek Apr. 28 at 7:16 PM
$MTNB this thing on....?
0 · Reply
24k369
24k369 Apr. 21 at 2:49 AM
$MTNB gotta have faith 🤘🏻
1 · Reply
emuziek
emuziek Apr. 21 at 12:30 AM
$MTNB - mighty thick new bags
0 · Reply
24k369
24k369 Apr. 20 at 10:24 PM
$MTNB just persevere
0 · Reply
Daveo460
Daveo460 Apr. 20 at 7:23 PM
$MTNB here we go guys, we are on the move,, 😂😂
0 · Reply
24k369
24k369 Apr. 18 at 12:41 AM
$MTNB
0 · Reply
Latest News on MTNB
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Apr 3, 2026, 5:00 PM EDT - 5 weeks ago

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Matinas BioPharma files to sell 16.9M shares of common stock for holders

2025-04-22T21:35:15.000Z - 1 year ago

Matinas BioPharma files to sell 16.9M shares of common stock for holders

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

2025-03-11T11:22:08.000Z - 1 year ago

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Feb 13, 2025, 5:00 PM EST - 1 year ago

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Matinas BioPharma appoints Evelyn D’An to board of directors

2025-02-07T12:36:00.000Z - 1 year ago

Matinas BioPharma appoints Evelyn D’An to board of directors

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Feb 7, 2025, 7:30 AM EST - 1 year ago

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Matinas BioPharma receives NYSE noncompliance notice

2025-01-10T22:20:26.000Z - 1 year ago

Matinas BioPharma receives NYSE noncompliance notice

Matinas BioPharma Receives NYSE Noncompliance Notice

Jan 10, 2025, 5:15 PM EST - 1 year ago

Matinas BioPharma Receives NYSE Noncompliance Notice

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

2024-11-01T20:05:25.000Z - 1 year ago

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

2024-10-31T12:13:24.000Z - 1 year ago

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

Matinas BioPharma downgraded to Hold from Buy at Maxim

2024-10-31T12:08:06.000Z - 1 year ago

Matinas BioPharma downgraded to Hold from Buy at Maxim

Matinas BioPharma says MAT2203 partnership negotiations terminated

2024-10-31T11:25:47.000Z - 1 year ago

Matinas BioPharma says MAT2203 partnership negotiations terminated

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Biotech Alert: Searches spiking for these stocks today

2024-09-05T15:05:09.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ABUS ASND BBIO ELAB

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma Holdings Transcript: Fireside Chat

Jun 18, 2024, 4:00 PM EDT - 2 years ago

Matinas BioPharma Holdings Transcript: Fireside Chat

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

May 16, 2024, 7:00 AM EDT - 2 years ago

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Matinas BioPharma Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q1 2024

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

May 9, 2024, 4:05 PM EDT - 2 years ago

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Matinas BioPharma Prices $10 Million Registered Direct Offering

Apr 3, 2024, 8:30 AM EDT - 2 years ago

Matinas BioPharma Prices $10 Million Registered Direct Offering

Matinas BioPharma Holdings Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q4 2023

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Mar 22, 2024, 9:15 AM EDT - 2 years ago

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Mar 22, 2024, 6:30 AM EDT - 2 years ago

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Feb 20, 2024, 7:30 AM EST - 2 years ago

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Dec 27, 2023, 7:30 AM EST - 2 years ago

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Dec 21, 2023, 7:30 AM EST - 2 years ago

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Matinas BioPharma Holdings Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:30 PM EST - 2 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q3 2023

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Nov 7, 2023, 7:30 AM EST - 2 years ago

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX TPST

Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Sep 27, 2023, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

Sep 22, 2023, 5:25 PM EDT - 2 years ago

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Aug 22, 2023, 7:30 AM EDT - 2 years ago

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2023

Aug 9, 2023, 4:30 PM EDT - 3 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2023

Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

Aug 2, 2023, 7:00 AM EDT - 3 years ago

Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

Jul 26, 2023, 8:00 AM EDT - 3 years ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

May 11, 2023, 7:30 AM EDT - 3 years ago

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

Matinas BioPharma Holdings Earnings Call Transcript: Q1 2023

May 10, 2023, 4:30 PM EDT - 3 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q1 2023

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

May 10, 2023, 4:05 PM EDT - 3 years ago

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

May 3, 2023, 7:00 AM EDT - 3 years ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

Matinas BioPharma Holdings Earnings Call Transcript: Q4 2022

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q4 2022

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Mar 15, 2023, 4:05 PM EDT - 3 years ago

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

Mar 8, 2023, 7:00 AM EST - 3 years ago

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Mar 2, 2023, 7:00 AM EST - 3 years ago

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Jan 30, 2023, 4:01 PM EST - 3 years ago

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

Jan 23, 2023, 7:00 AM EST - 3 years ago

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

Jan 17, 2023, 10:30 AM EST - 3 years ago

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

Jan 12, 2023, 7:00 AM EST - 3 years ago

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

Matinas BioPharma Holdings Earnings Call Transcript: Q3 2022

Nov 2, 2022, 4:30 PM EDT - 3 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q3 2022

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Nov 2, 2022, 4:02 PM EDT - 3 years ago

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Oct 21, 2022, 7:48 AM EDT - 3 years ago

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Oct 19, 2022, 7:10 AM EDT - 3 years ago

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Oct 12, 2022, 7:00 AM EDT - 3 years ago

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Matinas BioPharma Announces Chairman Succession Plan

Sep 21, 2022, 7:00 AM EDT - 3 years ago

Matinas BioPharma Announces Chairman Succession Plan

Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Aug 11, 2022, 6:30 AM EDT - 4 years ago

Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2022

Aug 10, 2022, 8:53 PM EDT - 4 years ago

Matinas BioPharma Holdings Earnings Call Transcript: Q2 2022

Matinas BioPharma to Participate in the BTIG Biotechnology Conference

Aug 1, 2022, 7:00 AM EDT - 4 years ago

Matinas BioPharma to Participate in the BTIG Biotechnology Conference

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

Jul 28, 2022, 4:15 PM EDT - 4 years ago

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

Daveo460
Daveo460 May. 12 at 2:01 AM
$MTNB the monthly chart looks good 😂
2 · Reply
Navtalk
Navtalk May. 8 at 11:51 AM
$MTNB any new in revise split?
0 · Reply
TheLawman
TheLawman May. 3 at 7:01 PM
$MTNB What has JJ been doing the last few years to earn his bloated salary?
0 · Reply
24k369
24k369 Apr. 30 at 4:50 AM
$MTNB Green Pastures
0 · Reply
emuziek
emuziek Apr. 28 at 7:16 PM
$MTNB this thing on....?
0 · Reply
24k369
24k369 Apr. 21 at 2:49 AM
$MTNB gotta have faith 🤘🏻
1 · Reply
emuziek
emuziek Apr. 21 at 12:30 AM
$MTNB - mighty thick new bags
0 · Reply
24k369
24k369 Apr. 20 at 10:24 PM
$MTNB just persevere
0 · Reply
Daveo460
Daveo460 Apr. 20 at 7:23 PM
$MTNB here we go guys, we are on the move,, 😂😂
0 · Reply
24k369
24k369 Apr. 18 at 12:41 AM
$MTNB
0 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:44 AM
$MTNB dead
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 6:01 PM
$MTNB RSI: 43.33, MACD: -0.0266 Vol: 0.05, MA20: 0.55, MA50: 0.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Daveo460
Daveo460 Apr. 7 at 9:29 PM
$MTNB well now, is jj gonna reverse split the rest of our remaining stocks out of existence?
0 · Reply
focafoca99
focafoca99 Apr. 6 at 1:51 AM
$MTNB said NYSE American flagged it for non-compliance on stockholders' equity, but the company says it plans to work through the cure process rather than face an immediate delisting move.
0 · Reply
HansDampf1
HansDampf1 Apr. 6 at 12:06 AM
$MTNB Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards Matinas BioPharma Holdings, Inc. Fri, April 3, 2026 at 11:00 PM GMT+2 5 min read https://finance.yahoo.com/sectors/healthcare/articles/matinas-biopharma-receives-notice-non-210000593.html
1 · Reply
george1sun2003
george1sun2003 Apr. 3 at 3:37 PM
$MTNB $CNVS hows this one working out for you? More bags?????😂😂😂😂😂😂😂😂
0 · Reply
tdohm22
tdohm22 Mar. 17 at 5:56 PM
$MTNB I guess I f*cking hallucinated we saved a f*cking foot amongst an unmet need 3 years ago.
2 · Reply
BiotechGoldenEra
BiotechGoldenEra Mar. 11 at 9:00 PM
$MTNB due for some pump group to come in
0 · Reply
AceofAllTrader
AceofAllTrader Mar. 8 at 12:15 AM
$MTNB In February 2025, Matinas entered into an agreement for a $3.3 million convertible preferred stock sale.
1 · Reply
Daveo460
Daveo460 Mar. 7 at 11:10 PM
$MTNB checking in again and I see nothing has changed yet again. Are there any longs left in this turd beside me?
5 · Reply
LiquidityRisk
LiquidityRisk Feb. 20 at 1:23 PM
$MTNB Matinas BioPharma develops lipid-based drug delivery. Clinical execution is the main driver. High development risk.
0 · Reply